Prevention & Lipids
Cardiovascular prevention
Primary and secondary prevention strategies
Emerging pathwayAlso known as: CV prevention, ASCVD prevention, cardiovascular risk
1,587
Clinical questions
25
Evidence-backed
100
Claims analyzed
Prevention & Lipids
Primary and secondary prevention strategies
Synthesized from 25 evidence-backed clinical questions linked to this topic — 4 supporting the intervention, 1 still contested.
The placed evidence leans toward benefit
4
Favor benefit
16% of all
0
Favor harm
0% of all
20 more (80%) still untested — not placed on the axis.
Insufficient certainty on 84% of questions
Does icosapent ethyl vs mineral_oil_placebo affect 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization) in Hypertriglyceridemia with cardiovascular risk?
Moderate Certainty+ Favors benefiticosapent ethyl vs mineral_oil_placebo · 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization)
1 studies (8,179 patients, 1 RCTs) provide moderate-certainty evidence for benefit of icosapent ethyl for 5-point MACE (CV death, non-fatal MI, non-fatal stroke, coronary revascularization, unstable angina) in Hypertriglyceridemia with cardiovascular risk.
Does icosapent ethyl vs mineral_oil_placebo affect Cardiovascular Mortality in Hypertriglyceridemia with cardiovascular risk?
Moderate Certainty+ Favors benefiticosapent ethyl vs mineral_oil_placebo · Cardiovascular Mortality
Emerging evidence with 100 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does icosapent ethyl vs mineral_oil_placebo affect Cardiovascular Mortality in Hypertriglyceridemia with cardiovascular risk?
Moderate Certainty+ Favors benefiticosapent ethyl vs mineral_oil_placebo · Cardiovascular Mortality
Does icosapent ethyl vs mineral_oil_placebo affect 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization) in Hypertriglyceridemia with cardiovascular risk?
Moderate Certainty+ Favors benefitThe effect of selected patient's characteristics on the choice of antihypertensive medication in the elderly in Slovakia
Pharmacoepidemiology and Drug Safety — Wawruch M — Aug 2009
Global Burden of Cardiovascular Diseases and its Risk Factors, 1990–2021: A Systematic Analysis for the Global Burden of Disease Study 2021
QJM — Tan S — Jan 2025
Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis
Clinical and Experimental Hypertension — Teramoto T — Jul 2013
The efficacy of multiple risk factor intervention in treated hypertensive men during long‐term follow up
Journal of Internal Medicine — Agewall S — Dec 1994
Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Cardiovascular prevention (also known as CV prevention, ASCVD prevention, cardiovascular risk). Primary and secondary prevention strategies
Synapse tracks 2 specific clinical questions in Cardiovascular prevention, each synthesized independently from its own trial evidence. They include: "Does icosapent ethyl vs mineral_oil_placebo affect Cardiovascular Mortality in Hypertriglyceridemia with cardiovascular risk?"; "Does icosapent ethyl vs mineral_oil_placebo affect 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization) in Hypertriglyceridemia with cardiovascular risk?".
As of 2026-08-19, the scientific consensus on Cardiovascular prevention is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/cardiovascular-prevention.
Deterministic synthesis from Synapse's enriched corpus — 112 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Cardiovascular prevention paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Cardiovascular prevention papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
1 studies (8,179 patients, 1 RCTs) provide moderate-certainty evidence for benefit of icosapent ethyl for Cardiovascular mortality in Hypertriglyceridemia with cardiovascular risk.
icosapent ethyl vs mineral_oil_placebo · 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization)
Current Opinion in Nephrology & Hypertension — Henrich W — Jul 2000
Across this topic’s most recent indexed papers.